Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B. [electronic resource]
Producer: 20171023Description: 358-365 p. digitalISSN:- 1665-2681
- Antiviral Agents -- adverse effects
- Biomarkers -- blood
- Computer Simulation
- Cost-Benefit Analysis
- DNA, Viral -- blood
- Disease Progression
- Drug Costs
- Drug Resistance, Viral
- Drug Substitution -- economics
- Drug Therapy, Combination
- Guanine -- analogs & derivatives
- Hepatitis B e Antigens -- blood
- Hepatitis B virus -- drug effects
- Hepatitis B, Chronic -- blood
- Humans
- Interferon-alpha -- economics
- Markov Chains
- Models, Economic
- Polyethylene Glycols -- economics
- Quality-Adjusted Life Years
- Recombinant Proteins -- economics
- Tenofovir -- economics
- Time Factors
- Treatment Outcome
- Viral Load
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.